Deutsche Bank Sees Buying Opportunity on Gilead Share Weakess

Deutsche Bank has published a research report on Gilead Sciences

stating that weakness in share prices is a buying opportunity. In the report, Deutsche Bank writes, "WHY WEAKNESS IS A BUYING OPPY'/WHY WE THINK" DISASTER SCENARIO IS UNLIKELY": (1) THIS IS NULL DATA- Navies are likely to look better. Likely GILD can take more than 15% market share. (2) GILD has an arsenal of OTHER DAAs they can combine to get a combo that can take 60% share. They likely can move that into clinic this summer in phase 2..and still be on track for phase 3 early 2013. (3) ALL THESE ASSUME LOW HIV- there is still potentially $10/share of UPSDIE IN HIV in 2012 is possible." Deutsche Bank maintains its $66 price target and Buy rating on Gilead Sciences, which closed yesterday at $54.81.